Please assess the completion status of the following clinical trial:

Trial Title: Dialysate Sodium Individualization in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ESKD on hemodialysis~* Hypertension, defined as average pre-HD BP \>150/85 mmHg or use of antihypertensive drugs~* Average pre-HD serum sodium \<139 mmol/L~Exclusion Criteria:~* Intradialytic hypotension~* Atrial fibrillation or other chronic tachyarrhythmia (due to effects on measuring equipment)~* Uncontrolled hypertension (average pre-HD BP \>200/105 mmHg)~* Uncontrolled diabetes mellitus (due to problems on interpretation of serum sodium values)~* Debilitating illness~* Inability to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- standard dialysate sodium (Type: ACTIVE_COMPARATOR): In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
- dialysate sodium individualization (Type: EXPERIMENTAL): .Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized).

Based on this trial design, predict the completion outcome and termination type (if applicable).